HSV has received much attention for its ability to kill tumor cells [173], with oncolytic HSV (oHSV), G207, being used in clinical advanced glioma trials, and CD133+ CSCs glioma cells being susceptible to tumor lysis by HSV [174]. This evidence concerns the gene PROM1 and neoplasm.